<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Fangzhou Inc. ( (HK:6086) ) has shared an update. Fangzhou Inc. reported a strong operational year in 2025, with revenue rising 30.2% to RMB3.53 billion as its consumer-facing healthcare platform continued to scale. The group recorded a net profit of RMB12.0 million, reversing a substantial loss in 2024, while adjusted net profit also improved and net assets increased, indicating a more resilient balance sheet and improved profitability. Key platform metrics underscored this momentum, with average monthly active users jumping 35% to 13.7 million and its network of registered doctors surpassing 251,000 by year-end. The company advanced its technology capabilities by launching the multimodal “XingShi” large language model to enhance clinical decision-making and cemented strategic partnerships with major pharmaceutical and technology players including Tencent, Novo Nordisk, Otsuka, and Innovent Biologics, strengthening its position in the digital healthcare ecosystem. The most recent analyst rating on (HK:6086) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page. More about Fangzhou Inc. Fangzhou Inc. is a Cayman Islands-incorporated company listed in Hong Kong that operates consumer-facing digital healthcare platforms. Its business focuses on connecting patients with medical professionals, leveraging technology such as large language models and data-driven tools to support clinical decision-making and collaboration with pharmaceutical partners across multiple therapeutic areas. Average Trading Volume: 25,609,703 Technical Sentiment Signal: Sell Current Market Cap: HK$2.06B </div>

06086

00700

TCEHY

TCTZF

Fangzhou Inc. (HK:6086) reported a 30.2% revenue increase to RMB3.53 billion in 2025, achieving a net profit of RMB12 million, reversing a loss from 2024. The company saw a 35% rise in average monthly active users to 13.7 million and expanded its network of registered doctors to over 251,000. Fangzhou launched the "XingShi" large language model to enhance clinical decision-making and formed strategic partnerships with major players like Tencent and Novo Nordisk. The current analyst rating for its stock is a Hold with a price target of HK$2.50.

- Fangzhou Inc. reported a strong operational year in 2025, with revenue increasing by 30.2% to RMB3.53 billion and a net profit of RMB12.0 million.  
- Key metrics included a 35% rise in average monthly active users to 13.7 million and the establishment of strategic partnerships with major players like Tencent and Novo Nordisk.  
- The current market cap stands at HK$2.06 billion, and the latest analyst rating for the stock is Hold with a price target of HK$2.50.

Fangzhou Swings to Profit as Revenue Surges and Digital Health Platform Expands